Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2

• Published in: The Journal of infection Vol. 85; no. 4; pp. e104 - e108
• Main Authors: Martin-Blondel, Guillaume, Marcelin, Anne-Genevieve, Soulié, Cathia, Kaisaridi, Sofia, Lusivika-Nzinga, Clovis, Dorival, Céline, Nailler, Laura, Boston, Anaïs, Melenotte, Cléa, Cabié, André, Choquet, Christophe, Coustillères, François, Martellosio, Jean-Philippe, Gaube, Géraldine, Trinh-Duc, Albert, Ronchetti, Anne-Marie, Pourcher, Valerie, Chauveau, Marie, Lacombe, Karine, Peiffer-Smadja, Nathan, Housset, Pierre, Perrot, Aurore, Pialoux, Gilles, Martin, Aurélie, Dubee, Vincent, Devaux, Mathilde, Frey, Jérôme, Cazanave, Charles, Liblau, Roland, Carrat, Fabrice, Yordanov, Youri
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.10.2022; Elsevier; The British Infection Association. Published by Elsevier Ltd
• Subjects: Antibodies, Monoclonal, Humanized / therapeutic use; Antibodies, Neutralizing; BA.2; COVID-19; Emerging diseases; Human health and pathology; Humans; Infectious diseases; Letter to the Editor; Life Sciences; Omicron; Pharmaceutical sciences; Pharmacology; SARS-CoV-2; Sotrovimab; SARS-CoV-2; Sotrovimab; Omicron; BA.2
• ISSN: 0163-4453; 1532-2742; 1532-2742
• DOI: 10.1016/j.jinf.2022.06.033

Before the Omicron era, the neutralizing antibody targeting the SARS-CoV2 Spike protein Sotrovimab has been shown to reduce the risk of COVID-19-related hospitalization in patients who are at high risk for progression. We recently showed that early administration of Sotrovimab in Omicron-infected patients with very high-risk for progression was associated with a low rate of COVID-19-related hospitalization within one month after treatment administration (3%), and with no death. However, the dominance of the Omicron sublineage BA.2 led health agencies to suspend Sotrovimab emergency use authorizations because of its lower neutralizing ability in vitro compared to BA.1 sublineage . Clinical efficiency of Sotrovimab to prevent COVID-19 related complications in high-risk patients with mild-to-moderate COVID-19 Omicron BA.2 remains unknown. Our aim was to compare the clinical and virological outcomes of Omicron BA.1 and BA.2-infected patients with mild-to-moderate COVID-19 who received 500 mg of Sotrovimab IV to prevent COVID-19-related complications.